Neoadjuvant Endocrine Therapy (NET) in breast cancer – COVID setting

Bardoli, Antonio D; Muttalib, Masoom

doi:10.1016/j.ejso.2021.11.022

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 76 Furthermore, a prospective observational study showed that patients with clinical node-negative breast cancer who received NET with multidisciplinary decision had similar rates for sentinel node positivity with historical control in the pre-COVID-19 era. 77 …”

Section: Net During Covid-19 Pandemicmentioning

confidence: 99%

Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy

Jeong,

Kim

2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

In recent years, endocrine therapy (ET), an effective systemic treatment for the management of estrogen receptor (ER)-positive breast cancers, has regained interest as a neoadjuvant therapy based on evidence that ET can fulfill the aim of neoadjuvant systemic treatment for tumor shrinkage as well as elucidate important clinical information on endocrine sensitivity that enables the prognostication of patients. Moreover, neoadjuvant endocrine therapy (NET) potentially provides an opportunity for early assessment of the clinical efficacy of novel agents. Furthermore, recently reported trials have generated evidence for a more tailored approach for perioperative management of ER-positive breast cancer using clinical and molecular biomarkers, and this has provided a rationale that enables the broadening of clinical indications for NET. This review discusses the current evidence for NET, the evolution of NET trials, clinical indications, and NET-based treatment strategies.

show abstract

Section: Net During Covid-19 Pandemicmentioning

confidence: 99%